Free Trial
LON:AVCT

Avacta Group (AVCT) Share Price, News & Analysis

GBX 72.90
+1.40 (+1.96%)
(As of 09/6/2024 ET)
Today's Range
70.65
73
50-Day Range
52.50
82.50
52-Week Range
39.63
166.98
Volume
1.71 million shs
Average Volume
2.40 million shs
Market Capitalization
£259.71 million
P/E Ratio
N/A
Dividend Yield
3.97%
Price Target
N/A
AVCT stock logo

About Avacta Group Stock (LON:AVCT)

Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

AVCT Stock Price History

AVCT Stock News Headlines

The death of Nvidia?
Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.
Avacta Group Plc (AVCTF)
Avacta Group: Appointment of Chief Business Officer
The death of Nvidia?
Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.
Appointment of Chief Business Officer
Avacta Group Share Chat
See More Headlines
Receive AVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/28/2020
Today
9/07/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

Net Income
£-24,950,000.00
Net Margins
-107.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£23.25 million
Cash Flow
GBX 4.86 per share
Book Value
GBX 8 per share

Miscellaneous

Free Float
N/A
Market Cap
£259.71 million
Optionable
Not Optionable
Beta
1.16
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Christina Marie Coughlin B.S. (Age 54)
    M.D., Ph.D., CEO, Interim Chief Medical Officer and Director
    Comp: $37k
  • Mr. Tony Gardiner (Age 53)
    CFO, Company Secretary & Executive Director
    Comp: $273k
  • Ms. Emma Wright
    Group In-House Counsel
  • Mr. Michael Vinegrad
    Group Communications Director
  • Mr. R. Craig Slater FCA (Age 60)
    Chief Operating Officer of Diagnostics
    Comp: $69k
  • Dr. Matt Johnson
    Chief Scientific Officer of Diagnostics
  • Mr. David Wilson
    Chief Commercial Officer of Diagnostics
  • Ms. Karen Harrison
    Chief Operating Officer of Therapeutics Division
  • Ms. Anne McGurk
    Joint Managing Director of Launch Diagnostics
  • Mr. Ian Jones
    Joint Managing Director of Launch Diagnostics

AVCT Stock Analysis - Frequently Asked Questions

How have AVCT shares performed this year?

Avacta Group's stock was trading at GBX 116.50 at the beginning of the year. Since then, AVCT stock has decreased by 37.4% and is now trading at GBX 72.90.
View the best growth stocks for 2024 here
.

How were Avacta Group's earnings last quarter?

Avacta Group Plc (LON:AVCT) posted its quarterly earnings results on Monday, September, 28th. The biotechnology company reported ($3.74) earnings per share (EPS) for the quarter. Avacta Group had a negative net margin of 107.31% and a negative trailing twelve-month return on equity of 116.58%.

How do I buy shares of Avacta Group?

Shares of AVCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Avacta Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avacta Group investors own include Legal & General Group (LGEN), SkinBioTherapeutics (SBTX), Augean (AUG), 7digital Group (7DIG), American Airlines Group (AAL), ACI Worldwide (ACIW) and Akero Therapeutics (AKRO).

This page (LON:AVCT) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners